Increased risk of pre-eclampsia reported in patients with PsA

Article

Previous studies have suggested a connection between rheumatic diseases, which often affect women in their reproductive years, and adverse pregnancy outcomes, such as pre-eclampsia.

Pregnant patients with psoriatic arthritis (PsA), although not pregnant women with axial spondyloarthritis (axSpA), were at an elevated risk of developing pre-eclampsia. In patients with rheumatoid arthritis (RA), risk factors included receiving combination therapy and high disease load during pregnancy, according to a study published in Rheumatic & Musculoskeletal Diseases.1

“RA, AxSpA, and PsA affect women in their reproductive years,” investigators explained. “Previous studies have indicated associations between these disorders and adverse pregnancy outcomes, for example, preterm birth, small for gestational age, and caesarean sections. The potential impact of disease activity and use of medication during pregnancy are causes for concern.”

Singleton pregnancies of patients with rheumatic diseases were identified via linking medical birth registers to Swedish Rheumatology Quality Register (SRQ) and Danish (DANBIO) rheumatology registries. Controls were then matched 1:10 for age, similarity, and birth year. Information on treatment 9 months prior to and during pregnancy, as well as functional status and disease activity during pregnancy, was collected. Only pregnancies of women registered in SRQ or DANIBO for 6 or more months prior to conception were included in the study.

Pregnant patients with RA, PsA, and AxSpA were compared with the control group and risks of pre-eclampsia, defined as new-onset hypertension and multiorgan failure, were estimated both overall and by disease load and antirheumatic treatment, which included corticosteroids, biological disease-modifying antirheumatic drugs (bDMARDs), and conventional synthetic DMARDs (csDMARDs), both as monotherapy and combination therapy. The disease load was analyzed using the Health Assessment Questionnaire ≥1, Disease Activity Score in 28 joints (DAS28-CRP) ≥3.2, and C-reactive protein (CRP) ≥10.

Ultimately, 69 (3.9%) patients with RA (n = 1739), 34 (4.2%) patients with axSpA (n = 819), and 26 (5.3%) patients with PsA (n = 489) experienced pre-eclampsia events. Patients with PsA were more likely to be less educated, smokers, and obese. The PsA cohort had an 85% increased risk of developing pre-eclampsia when compared with controls (adjusted odds ratio [aOR] 1.85 (1.10 to 3.12). The corresponding aOR for axSpA patients was 1.17 (95% CI 0.76 to 1.78). Risk was only slightly increased in patients with RA (1.27; 0.96 to 1.67).

Monotherapy prior to pregnancy was linked to pre-eclampsia in the PsA group (2.72; 1.4 to 5.13). Patients with RA receiving combination therapy both before and during pregnancy had a higher risk of developing pre-eclampsia (1.59; 1.07 to 2.37 and 1.53; 0.97 to 2.39, respectively). Additionally, a high disease load doubled the risk of developing pre-eclampsia in the RA cohort (aOR 1.96; 1.26 to 3.04).

Strengths include the large size of pregnancy cohorts from comprehensive Scandinavian registries, which allowed investigators to eliminate recall bias and adjust for covariates. Multiple data sources were combined to ensure the most accurate treatment information and disease activity was included, which had not been previously possible.

However, the number of pre-eclampsia events were low, thus reducing statistical power. Further, disease activity and treatment information were not available in a substantial proportion of pregnancies. Future studies focusing on a close follow-up of women before and early in pregnancy would be beneficial.

“From a clinical perspective, our findings add to the field of knowledge, by informing clinicians of the underlying risk of pre-eclampsia in these patient populations and by emphasizing the importance of monitoring women with, in particular, RA and PsA regarding this risk,” investigators concluded.

Reference:

Secher AEP, Granath F, Glintborg B, Rom A, Hetland ML, Hellgren K. Risk of pre-eclampsia and impact of disease activity and antirheumatic treatment in women with rheumatoid arthritis, axial spondylarthritis and psoriatic arthritis: a collaborative matched cohort study from Sweden and Denmark. RMD Open. 2022;8(2):e002445. doi:10.1136/rmdopen-2022-002445


This article originally appeared on Rheumatology Network®.

Related Videos
Navigating vasomotor symptoms in breast cancer patients | Image Credit: menopausefoundationcanada.ca.
Fertility counseling for oncology patients | Image Credit: allhealthtv.com
Learning what women prefer in STI preventive care
The impact of smoking cessation on pregnancy outcomes | Image Credit: rwjmg.rwjms.rutgers.edu
USPSTF releases new recommendations for breast cancer screening | Image Credit: uclahealth.org
Maximizing maternal health: The impact of exercise during pregnancy | Image Credit: cedars-sinai.org
Understanding combined oral contraceptives and breast cancer risk | Image Credit: health.ucdavis.edu
Why doxycycline PEP lacks clinical data for STI prevention in women
© 2024 MJH Life Sciences

All rights reserved.